EU Pharmacovigilance Strategy: Public consultation on draft legislative proposals
DG Enterprise and Industry wishes to consult stakeholders on legislative proposals to strengthen and rationalise the EU system of pharmacovigilance. The Commission services conducted a previous consultation, between 16 March 2006 and 12 May 2006, which sought stakeholders' views on the strengths and weaknesses of the current EU system of pharmacovigilance and how the system could be strengthened. The Largest Pharmaceutical Companies and Britain's Serious Fraud Office in the News
A UK government probe into whether GlaxoSmithKline, AstraZeneca and Eli Lilly & Co bribed the Saddam Hussein administration in Iraq may expand to other...
British ask Lilly for data on Iraq sales
British fraud investigators are questioning Eli Lilly and Co. and at least two other drug makers about possible kickbacks they paid to trade...
UK pulls Glaxo into Iraq fraud probe
Serious Fraud Office has requested documents from GlaxoSmithKline as part of an investigation into kickbacks or bribes that may have...
Transinsight's GoPubMed with Social Networking Features for Biomedical Experts
EMEA concludes new advice to doctors and patients for Champix needed
The European Medicines Agency (EMEA) has concluded that updated warnings to doctors and patients are needed to increase awareness of cases of suicidal ideation and suicide attempts reported in patients using Champix (varenicline), a medicine indicated for smoking cessation in adults. EMEA recommends withdrawal of the marketing authorisations for lumiracoxib-containing medicines
The European Medicines Agency (EMEA) has recommended the withdrawal of the marketing authorisations for all lumiracoxib-containing medicines, because of the risk of serious side effects affecting the liver. Lumiracoxib is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the group 'COX-2 inhibitors'. It is used for symptomatic relief in the treatment of osteoarthritis of the hip and knee. 5. In the Absence of Direct-to-Consumer Advertising, Online Content Is Critical
European consumers have been a longneglected piece of the strategic puzzle for most marketers at health and pharmaceutical companies. Yet, signs increasingly point to the degree to which European consumers are, in fact, researching health information and treatment options, and ultimately taking action as a result of those information searches - as outlined in the trend above. More Pharma News ...
Business & Industry
- Pfizer to supply Global Fund up to 6 million PAXLOVID™ treatment courses for low-and-middle-income countries
- WHO grants prequalification to GSK's Mosquirix - the first and only approved malaria vaccine
- Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in European Union
- Novartis invests in early technical development capabilities for next-generation biotherapeutics
- FDA grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus vaccine candidate
Research & Development
- National CDC-funded study confirms that mRNA vaccines protect against serious COVID-19 during pregnancy
- 2nd Annual Next Generation Pharmaceutical Cleanrooms Conference
- Shutting down backup genes leads to cancer remission in mice
- Bird's enzyme points toward novel therapies
- WHO strongly advises against antibody treatments for COVID-19 patients
- Mucosal antibodies in the airways protect against omicron infection
- Drug turns cancer gene into "eat me" flag for immune system
Conferences & Events
- SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
- Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
- SMi's 22nd Annual Pain Therapeutics Conference
- SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
- SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
- SMi's 3rd Annual AI in Drug Discovery Conference
- SMi's 6th Annual Highly Potent Active Pharmaceutical Ingredients
Regulatory Affairs
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
- FDA approves first systemic treatment for alopecia areata
- FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
- FDA limits use of Janssen COVID-19 vaccine to certain individuals
- EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice